These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17405890)

  • 1. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
    Colozza M; de Azambuja E; Personeni N; Lebrun F; Piccart MJ; Cardoso F
    Oncologist; 2007 Mar; 12(3):253-70. PubMed ID: 17405890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
    Colozza M; de Azambuja E; Cardoso F; Bernard C; Piccart MJ
    Oncologist; 2006 Feb; 11(2):111-25. PubMed ID: 16476832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
    Dellapasqua S; Castiglione-Gertsch M
    Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
    Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
    Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the treatment of metastatic breast cancer.
    Gralow JR
    Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
    Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
    Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on endocrine therapy for breast cancer.
    Buzdar AU; Hortobagyi G
    Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line chemotherapy for metastatic breast cancer.
    Telli ML; Carlson RW
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
    Munzone E; Curigliano G; Rocca A; Bonizzi G; Renne G; Goldhirsch A; Nolè F
    Breast Cancer Res; 2006; 8(1):R4. PubMed ID: 16417653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
    Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.